Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Target Price at $21.07

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $21.07.

IOVA has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. Piper Sandler decreased their price target on Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a report on Friday, January 31st.

Iovance Biotherapeutics Stock Down 3.8 %

Shares of NASDAQ:IOVA opened at $5.34 on Friday. Iovance Biotherapeutics has a twelve month low of $5.05 and a twelve month high of $18.33. The stock’s 50 day moving average is $6.35 and its 200-day moving average is $8.66. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.58 and a beta of 0.54.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. grew its stake in Iovance Biotherapeutics by 39.4% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 5,500 shares during the period. GF Fund Management CO. LTD. bought a new position in Iovance Biotherapeutics in the 4th quarter valued at $47,000. Neo Ivy Capital Management bought a new position in Iovance Biotherapeutics in the 4th quarter valued at $3,353,000. Stempoint Capital LP bought a new position in Iovance Biotherapeutics in the 4th quarter valued at $7,026,000. Finally, Shay Capital LLC bought a new position in Iovance Biotherapeutics in the 4th quarter valued at $188,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.